Project Description

Since 29 July 2016, the National Institute for Health and Care Excellence (NICE) has employed a new fast-track appraisal process for oncology drugs. The aim of this process is to provide patients earlier access to new, more effective medicines. This study investigates the extent to which these targets have been met for cancer drugs receiving market access post-July 2016, in order to determine whether NICE’s new process is translating into faster patient access in practice.

Read our findings here…. (Faster patient access with the new NICE appraisal process?)